Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205333 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02205333 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 48 participants.
The verdict
NCT02205333, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.
Interventions
- BIOLOGICAL MEDI6469 Monotherapy
- BIOLOGICAL MEDI6469 Plus Tremelimumab
- BIOLOGICAL MEDI6469 Plus Durvalumab
- BIOLOGICAL MEDI6469 plus Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2016-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02205333
The ClinicalTrials.gov registry entry for NCT02205333 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MEDI6469 Monotherapy is the first listed.
NCT02205333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02205333 about?
NCT02205333 is a clinical study titled "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies". The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelim...
What is the current status of trial NCT02205333?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-08-13. Estimated completion is 2016-04-08.
What interventions are being tested in trial NCT02205333?
The interventions under investigation include: MEDI6469 Monotherapy (BIOLOGICAL), MEDI6469 Plus Tremelimumab (BIOLOGICAL), MEDI6469 Plus Durvalumab (BIOLOGICAL), MEDI6469 plus Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02205333?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.